Status | Study |
Active, not recruiting |
Study Name: Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW) Condition: Coronavirus Infections Date: 2022-08-21 Interventions: Biological: Pfizer BNT162b2 VaccineThe Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-base |
RECRUITING |
Study Name: COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor Condition: Coronavirus Infections Date: 2020-03-19 Interventions: Not required |
Recruiting |
Study Name: MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b Condition: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Date: 2016-06-20 Interventions: Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b |
Active, not recruiting |
Study Name: Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults Condition: Middle East Respiratory Syndrome Coronavirus Date: 2016-05-28 Interventions: Biological: SAB-301 SAB-301 is |
Completed |
Study Name: Saudi Outcomes of ECMO-treated MERS-CoV Patients Condition: MERS-CoV Infection Refractory Hypoxemia Date: 2015-12-04 Interventions: Other: Extracorporeal Membrane Oxygenation |
Completed |
Study Name: Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) Condition: Viral Infection Date: 2015-11-11 Interventions: Other: Risk of MERS infection HCPs, patients and layperson to closely or indirectly contact a case-patie |
Completed |
Study Name: Seroprevalence of MERS-CoV IgG in Healthcare Workers Condition: Coronavirus Infections Date: 2015-07-06 |
Active, not recruiting |
Study Name: Anti-MERS-COV Convalescent Plasma Therapy Condition: Respiratory Distress Syndrome (& [Hyaline Membrane Disease]) Date: 2014-06-12 Interventions: Biological: Convalescent plasma Convalescent plasma from patients who recently recovered from MERS-CoV, |
Withdrawn |
Study Name: Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study Condition: SARS Date: 2011-06-16 Interventions: Drug: Aluminum hydroxide adjuvant (Alhydrogel®) |
Completed |
Study Name: Collection and Testing of Respiratory Samples Condition: QIAGEN ResPlex II Advanced Panel Influenza A Respiratory S Date: 2011-02-18 Interventions: Device: artus Influenza A/B RT-PCR Test The investigational assay, used for detecting the presence of In |